Proton Pump Inhibitors Associated with Higher Incidence of Mucositis in Patients Receiving Methotrexate for Graft Vs Host Disease Prophylaxis

Graft-versus-host disease (GVHD) is a major complicating factor in determining morbidity and mortality following allogeneic stem cell transplant. To prevent GVHD, our institution administers calcineurin inhibitors and low doses of methotrexate (MTX) (5-15 mg/m2) on days +1, +3, +6, +11 for GVHD prophylaxis.Proton pump inhibitors (PPIs) are used for the treatment of gastroesophageal reflux disease, pyrosis, and/or peptic ulcer disease. PPIs have been shown to inhibit the ATP-binding cassette drug transporter Breast Cancer Resistance Protein's (BCRP/ABCG2) ability to excrete methotrexate into the urine in a concentration-dependent manner.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Luke Mountjoy, Daniel Almquist, Henry Ofori, Marlene Girardo, Margaret McCallen Tags: 252 Source Type: research